RecruitingPhase 1NCT04323046
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
Studying Glioblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sabine Mueller, MD, PhD
- Principal Investigator
- Tom Davidson (tdavidson@chla.usc.edu), MDChildren's Hospital Los Angeles
- Intervention
- Nivolumab(biological)
- Enrollment
- 20 target
- Eligibility
- 25 years · All sexes
- Timeline
- 2020 – 2029
Study locations (20)
- University of Alabama at Birmingham, Children's of Alabama, Birmingham, Alabama, United States
- Children's Hospital of Los Angeles, Los Angeles, California, United States
- Rady Children's Hospital, San Diego, California, United States
- University of California, San Francisco, San Francisco, California, United States
- Children's National Hospital, Washington D.C., District of Columbia, United States
- University of Florida, Gainesville, Florida, United States
- Riley Children's Hospital, Indianapolis, Indiana, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Washington University St. Louis, St Louis, Missouri, United States
- Hackensack Meridian Children's Health at Joseph M. Sanzari Children's Hospital, Hackensack, New Jersey, United States
- Duke Children's Hospital & Health Center, Durham, North Carolina, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- University of Utah, Salt Lake City, Utah, United States
- Sydney Children's Hospital, Sydney, New South Wales, Australia
- +5 more locations on ClinicalTrials.gov
Collaborators
Pediatric Neuro-Oncology Consortium
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04323046 on ClinicalTrials.govOther trials for Glioblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07326566Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIIBlack Diamond Therapeutics, Inc.
- RECRUITINGPHASE1, PHASE2NCT07501559A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)Jecho Biopharmaceuticals Co., Ltd.
- RECRUITINGPHASE1NCT07464925A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade GliomaTetragon Biosciences Ltd
- RECRUITINGNCT07411690Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial TumorsMedical University of Warsaw
- RECRUITINGPHASE1NCT07480941Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade GliomaBeijing Biotech
- RECRUITINGPHASE2NCT07225621Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed GlioblastomaAlpheus Medical, Inc.
- RECRUITINGPHASE1, PHASE2NCT073912155G-PEARL: Paxalisib in Malignant Brain TumoursInstitute of Cancer Research, United Kingdom
- RECRUITINGNANCT07426848OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour PatientsRoyal College of Surgeons, Ireland